drugset

drugset / Trial / NCT05109091

Study of ATH434 in Participants with Multiple System Atrophy

NCT05109091 ↗

Phase 2 Completed 77 enrolled Alterity Therapeutics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

Timeline

Start: 2022-07-01
Primary completion: 2024-11-28
Completion: 2024-11-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PBT-434	Small molecule	—	—

Indications